FREQUENTLY ASKED QUESTIONS ABOUT OCTANE · FREQUENTLY ASKED QUESTIONS ABOUT OCTANE What is the...

FREQUENTLY ASKED QUESTIONS ABOUT OCTANE What is the OCTANE study? The Ontario-wide Cancer TArgeted Nucleic Acid Evaluation (OCTANE) study is increasing the use of a technology known as genomic sequencing at five Ontario hospitals. By using this technology and collecting tissue samples from participants the study will: 1) assist patients and their physicians in finding approved or experimental therapies that may be of benefit by slowing the growth of their cancer; and 2) create a repository of tumor and biological samples and data to aid in future cancer research projects. The study will also establish a system for cancer researchers to share data across Ontario. What is genomic sequencing? Genomic sequencing is a technology that allows technicians to process a blood or tissue sample to gain detailed information about some or all of the genes contained with the DNA and also possibly RNA. How can results from genomic sequencing factor into cancer treatment? By looking at the results of genomic sequencing, doctors can see which genes have been altered or mutated, including those that are potentially driving the growth a patient’s cancer. Doctors can then attempt to find new or existing therapies that “target” the gene or genes that have been identified. Each individual’s cancer has unique characteristics, and genomic sequencing helps doctors adapt treatment to the specifics of a patient’s cancer. What types of cancer are included in the OCTANE study? OCTANE is for advanced solid tumours, such as: breast, lung, colorectal, melanoma, gynaecological, genitourinary, pancreatobiliary, gastrointestinal, head and neck, rare cancers, and unknown primary cancers. How do I enrol in the OCTANE study? There are very specific criteria for participating in the OCTANE study. Full requirements are available at: https://clinicaltrials.gov/ct2/show/NCT02906943, under the heading “Eligibility”. Patients must already be undergoing treatment at one of the cancer centres listed below and must not have received more than two lines of cytotoxic therapy for recurrent or metastatic disease. Patients can apply to enrol in the study or find out more by contacting the person at their cancer centre in the list below.

Upload
others
Category

Documents
view
32
download
0

Embed Size (px):

Transcript of FREQUENTLY ASKED QUESTIONS ABOUT OCTANE · FREQUENTLY ASKED QUESTIONS ABOUT OCTANE What is the...

FREQUENTLY ASKED QUESTIONS ABOUT OCTANE What is the OCTANE study?

The Ontario-wide Cancer TArgeted Nucleic Acid Evaluation (OCTANE) study is increasing the use of a technology known as genomic sequencing at five Ontario hospitals. By using this technology and collecting tissue samples from participants the study will: 1) assist patients and their physicians in finding approved or experimental therapies that may be of benefit by slowing the growth of their cancer; and 2) create a repository of tumor and biological samples and data to aid in future cancer research projects. The study will also establish a system for cancer researchers to share data across Ontario.

What is genomic sequencing?

Genomic sequencing is a technology that allows technicians to process a blood or tissue sample to gain detailed information about some or all of the genes contained with the DNA and also possibly RNA.

How can results from genomic sequencing factor into cancer treatment?

By looking at the results of genomic sequencing, doctors can see which genes have been altered or mutated, including those that are potentially driving the growth a patient’s cancer. Doctors can then attempt to find new or existing therapies that “target” the gene or genes that have been identified. Each individual’s cancer has unique characteristics, and genomic sequencing helps doctors adapt treatment to the specifics of a patient’s cancer.

What types of cancer are included in the OCTANE study?

OCTANE is for advanced solid tumours, such as: breast, lung, colorectal, melanoma, gynaecological, genitourinary, pancreatobiliary, gastrointestinal, head and neck, rare cancers, and unknown primary cancers.

How do I enrol in the OCTANE study?

There are very specific criteria for participating in the OCTANE study. Full requirements are available at: https://clinicaltrials.gov/ct2/show/NCT02906943, under the heading “Eligibility”. Patients must already be undergoing treatment at one of the cancer centres listed below and must not have received more than two lines of cytotoxic therapy for recurrent or metastatic disease. Patients can apply to enrol in the study or find out more by contacting the person at their cancer centre in the list below.